Martinez-Lopez, 167 patient HCQ late treatment study: 33% lower mortality [p=0.2] https://c19p.org/martinezlopez
copied to clipboard
Multiple Myeloma and SARS-CoV-2 Infection: Clinical Characteristics and Prognostic Factors of Inpatient Mortality
et al., Blood Cancer Journal, doi:10.1038/s41408-020-00372-5
Retrospective 167 multiple myeloma patients in Spain.
|
risk of death, 33.0% lower, RR 0.67, p = 0.20, treatment 47 of 148 (31.8%), control 9 of 19 (47.4%), NNT 6.4.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Martinez-Lopez et al., 6/30/2020, retrospective, Spain, Europe, peer-reviewed, median age 71.0, 25 authors.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.